**TABLE 1**

**Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazone group**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Placebo group | | Troglitazone group | | | *p* |
| *n* |  | |  | | |  |
| Clinical characteristics |  | |  | | |  |
| Age (years) | 34.3 | ± 6.5 | 34.9 | ± 6.6 | | 0.52 |
| BMI (kg/m²) | 30.3 | ± 5.3 | 30.6 | ± 6.1 | | 0.63 |
| Waist-to-hip circumference ratio | 0.86 | ± 0.05 | 0.85 | ± 0.06 | | 0.19 |
| Using hormonal contraceptives\* | 48% |  | 43% |  | | 0.41 |
| OGTT |  |  |  | | |  |
| Fasting glucose (mg/dl) | 98.1 | ± 9.1 | 98.7 | | ± 1.02 | 0.64 |
| 2-h glucose | 154.0 | ± 24.0 | 154.4 | | ± 27.0 | 0.97 |
| Total glucose area (mg/dl x min x 10-³) | 18.7 | ± 2.0 | 18.9 | | ± 2.0 | 0.25 |
| Impaired glucose tolerance | 72% |  | 69% | |  | 0.66 |
| Fasting insulin (uU/ml) | 16.0 | ± 7.5 | 17.0 | | ± 10.8 | 0.82 |
| Total insulin area (uU/ml x min) | 10,209 | ± 5536 | 9,902 | | ± 6543 | 0.55 |
| IVGTT |  |  |  | |  |  |
| Total glucose area (mg/dl x min x 10 | 94.3 | ± 10.4 | 94.8 | | ± 10.2 | 0.71 |
| Age (years) | 1.48 | ± 0.40 | 1.42 | | ± 0.39 | 0.23 |
| BMI (kg/m²) | 18.7 | ± 9.7 | 16.6 | | ± 9.5 | 0.05 |
| Waist-to-hip circumference ratio | 2.28 | ± 1.75 | 2.64 | | ± 1.70 | 0.05 |
| Age (years) | 569 | ± 527 | 454 | | ± 360 | 0.18 |
| BMI (kg/m²) | 10,686 | ± 5686 | 9,273 | | ± 5434 | 0.03 |
| Waist-to-hip circumference ratio | 983 | ± 697 | 976 | | ± 717 | 0.99 |